Literature DB >> 21659461

Prognostic immune markers in non-small cell lung cancer.

Kei Suzuki1, Stefan S Kachala, Kyuichi Kadota, Ronglai Shen, Qianxing Mo, David G Beer, Valerie W Rusch, William D Travis, Prasad S Adusumilli.   

Abstract

Tumor-associated immune responses have polarized effects in regulating tumor growth. Although a clear association has been shown between the tumor immune response and clinical outcome in colorectal and ovarian cancers, the role of immune markers for stratifying prognosis in non-small cell lung cancer (NSCLC) is less defined. Herein, we review the prognostic significance of published immune markers in the tumor microenvironment and peripheral blood of NSCLC patients. To identify prognostic immune genes, we reviewed all published gene-profiling studies in NSCLC and delineated the significance of immune genes by doing subanalysis on the microarray database of the NIH Director's Challenge study. This first comprehensive review of prognostic immune markers provides a foundation for further investigating immune responses in NSCLC. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21659461     DOI: 10.1158/1078-0432.CCR-10-2805

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  72 in total

Review 1.  Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.

Authors:  Marissa Mayor; Neng Yang; Daniel Sterman; David R Jones; Prasad S Adusumilli
Journal:  Eur J Cardiothorac Surg       Date:  2015-10-29       Impact factor: 4.191

2.  DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.

Authors:  Jana Jeschke; Martin Bizet; Christine Desmedt; Emilie Calonne; Sarah Dedeurwaerder; Soizic Garaud; Alexander Koch; Denis Larsimont; Roberto Salgado; Gert Van den Eynden; Karen Willard Gallo; Gianluca Bontempi; Matthieu Defrance; Christos Sotiriou; François Fuks
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

3.  Lung Cancer Subtypes Generate Unique Immune Responses.

Authors:  Stephanie E Busch; Mark L Hanke; Julia Kargl; Heather E Metz; David MacPherson; A McGarry Houghton
Journal:  J Immunol       Date:  2016-10-31       Impact factor: 5.422

4.  Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer.

Authors:  Yuan Gao; Wen-Jie Wang; Qiaoming Zhi; Meng Shen; Min Jiang; Xiaojie Bian; Fei-Ran Gong; Chong Zhou; Lian Lian; Meng-Yao Wu; Jun Feng; Min Tao; Wei Li
Journal:  Oncotarget       Date:  2017-09-27

Review 5.  Lung cancer: Biology and treatment options.

Authors:  Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal:  Biochim Biophys Acta       Date:  2015-08-19

6.  Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Hideki Ujiie; Daniel H Buitrago; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

Review 7.  Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.

Authors:  Mauricio Burotto; Anish Thomas; Deepa Subramaniam; Giuseppe Giaccone; Arun Rajan
Journal:  J Thorac Oncol       Date:  2014-11       Impact factor: 15.609

Review 8.  Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy.

Authors:  Dirk De Ruysscher; Jianyue Jin; Tim Lautenschlaeger; Jin-Xiong She; Zhongxing Liao; Feng-Ming Spring Kong
Journal:  Transl Lung Cancer Res       Date:  2017-12

9.  AKIP1 promoted epithelial-mesenchymal transition of non-small-cell lung cancer via transactivating ZEB1.

Authors:  Xiaobin Guo; Limin Zhao; Dongjun Cheng; Qing Mu; Hongyan Kuang; Keqing Feng
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

10.  IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.

Authors:  Weili Wang; Lei Huang; Jian-Yue Jin; Shruti Jolly; Yong Zang; Huanmei Wu; Li Yan; Wenhu Pi; Lang Li; Andrew L Mellor; Feng-Ming Spring Kong
Journal:  Cancer Res       Date:  2017-11-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.